• About
    • Our Team
    • Clinical Advisory Board
    • Board of Directors
  • Product
  • Investors & Partners
  • News
  • Contact

News

Zucara Therapeutics Reports Positive Results from Phase 1b Trial of ZT-01

June 22, 2022 by zucaraadmin

– Proof-of-Concept Trial Confirms ZT-01’s Mechanism of Action in Restoring Glucagon Release in Patients with Type 1 Diabetes – –

read more

Zucara Therapeutics Secures Additional Funding from GlycoNet and Mitacs for the Development of ZT-01

May 2, 2022 by zucaraadmin

Zucara Therapeutics Secures Additional Funding from GlycoNet and Mitacs for the Development of ZT-01 – Second grants from GlycoNet and

read more

Zucara Therapeutics Announces Publication of Preclinical Study Demonstrating ZT-01’s Ability to Restore Glucagon Release in Type 1 Diabetes

February 8, 2022 by zucaraadmin

Zucara Therapeutics Announces Publication of Preclinical Study Demonstrating ZT-01’s Ability to Restore Glucagon Release in Type 1 Diabetes – ZT-01

read more

Zucara Therapeutics Doses First Patients in Phase 1b Trial of ZT-01

July 28, 2021 by zucaraadmin

Zucara Therapeutics Doses First Patients in Phase 1b Trial of ZT-01 – Proof-of-Concept Trial to Evaluate the Effect of ZT-01

read more

Zucara Therapeutics Successfully Completes Single and Multiple Ascending Dose Phase 1 Trial of ZT-01

May 26, 2021 by zucaraadmin

Zucara Therapeutics Successfully Completes Single and Multiple Ascending Dose Phase 1 Trial of ZT-01 Toronto, Canada, May 26, 2021 –

read more

Zucara Therapeutics Expands ZT-01 Development Program to Type 2 Diabetes

November 2, 2020 by zucaraadmin

Zucara Therapeutics Expands ZT-01 Development Program to Type 2 Diabetes – ZT-01 Development for T2D to be Supported by Nearly

read more

Zucara Therapeutics Doses First Subject in Phase 1 Trial of ZT-01

September 29, 2020 by zucaraadmin

Zucara Therapeutics Doses First Subject in Phase 1 Trial of ZT-01 – Phase 1 Trial to Evaluate ZT-01 for the

read more

Zucara Therapeutics Announces US$21 Million Series A Financing

March 31, 2020 by zucaraadmin

Zucara Therapeutics Announces US$21 Million Series A Financing – Proceeds to Fund Development of ZT-01 Through Phase 2 Clinical Trials

read more

Zucara Therapeutics Presents New Data at European Association for the Study of Diabetes

September 19, 2019 by zucarastaff

Dr. Richard Liggins, Chief Scientific Officer, presenting at EASD in Barcelona. TORONTO, Canada and BARCELONA, Spain: Zucara Therapeutics Inc., a

read more

Zucara Therapeutics Secures Grant from GlycoNet to Expand and Validate their Drug Therapy Model for Type 1 Diabetes to Type 2 Diabetes

July 12, 2019 by zucarastaff

Toronto & Vancouver, Canada:  Zucara Therapeutics Inc., a life sciences company developing the first once-daily therapeutic to prevent hypoglycemia in

read more
  • 1
  • 2
  • 3
  • Next Page»

OUR PARTNERS





CATEGORIES

  • News

Copyright 2022 Zucara Therapeutics, all rights reserved.